abciximab (Rx)

Brand and Other Names:ReoPro
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injectable solution

  • 2mg/mL

Adjunct to PCI

Prevention of cardiac ischemic complications in patients undergoing PCI

0.25 mg/kg IV bolus over at least 1 min, 10-60 min before start of PCI, THEN

0.125 mcg/kg/min IV continuous infusion for 12 hr; not to exceed infusion rate of 10 mcg/min  

Unstable Angina

Indicated for prevention of cardiac complications in patients with unstable angina with PCI planned within 24 hr

0.25 mg/kg IV bolus over at least 1 minute, THEN

0.125 mcg/kg/min IV continiuous infusion for 18-24 hr concluding 1 hour post-PCI; not to exceed 10 mcg/min  

Stop continuous infusion of abciximab in patients with failed PCIs

Other Indications & Uses

Adjunctive therapy during thrombolysis (off-label)

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and abciximab

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            >10%

            Bleeding, minor (70-82%)

            Bleeding, major (17-21%)

            Hypotension (14-21%)

            Back pain (17.6%)

            Nausea (13.6%)

            Chest pain (11.4%)

            Vomiting (7-11%)

            1-10%

            Headache (6%)

            Thrombocytopenia (2-6%)

            Bradycardia (5%)

            Injection site pain (3.6%)

            Extremity pain (3.5%)

            Abdominal pain (3%)

            UTI (2%)

            Dizziness (1.8%)

            Peripheral edema (1.6%)

            Anemia (1.2%)

            Diarrhea (1%)

            Hypoesthesia (1%)

            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity

            Active major bleeding, thrombocytopenia, history of CVA (within 2 years)

            Peptic ulcer disease

            Recent surgery of trauma, intracranial neoplasm, uncontrolled HTN, vasculitis

            Oral anticoagulant use within 7 days increases bleeding risk

            Cautions

            Intended for use with aspirin and heparin, and has only been studied in that setting

            Increased bleeding risk when used with thrombolytic agents

            Thrombocytopenia

            • Monitor platelet counts prior to, during, and after treatment
            • Acute decreases in platelet count should be differentiated between true thrombocytopenia and pseudothrombocytopenia
            • If true thrombocytopenia is verified, therapy should be immediately discontinued and the condition appropriately monitored and treated
            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: not known if excreted in breast milk; use caution

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Chimeric monoclonal antibody; prevents binding of fibrinogen, vWF to glycoprotein IIb/IIIa receptor sites on platelets

            Pharmacokinetics

            Half-life: 30 min

            Onset: 10 min (<20% of baseline)

            Duration: 72 hr

            Metabolism: Through proteolytic cleavage

            Platelet binding: Remains bound for 15 days

            Peak time: ~30 min (platelet inhibition)

            Previous
            Next:

            Administration

            IV Compatibilities

            Solution: D5W, NS

            Y-site: adenosine, atropine, bivalirudin, diphenhydramine, fentanyl, metoprolol, midazolam

            IV Preparation

            Do not add any other drugs in same IV line

            Bolus injection: withdraw through 0.22 micron filter

            Infusion: withdraw 4.5 mL (9 mg) through filter into syringe; inject into 250 mL of NS or D5W; final concentration 35 mcg/mL

            Do not shake vial

            IV Administration

            Bolus over at least 1 min

            See adult dosing for infusion rate

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.